Abbreviations
=============

AZA

:   Azacitidine (5-azacytidine)

CTA

:   Cancer-testis antigen or cancer-germline antigen

CTAG1B

:   Cancer/testis antigen 1B

DAC

:   Decitabine (5-aza-2′-deoxycitidine)

DNA

:   Deoxyribonucleic acid

DNMTi

:   DNA methyltransferase inhibitor

EOC

:   Epithelial ovarian cancer

HLA

:   Human leukocyte antigen

ICAM-1

:   Intracellular Adhesion Molecule 1

LINE-1

:   Long interspersed nuclear element-1

MAGE-A

:   Melanoma antigen family A

MHC

:   Major histocompatibility complex

NY-ESO-1

:   New york esophageal squamous cell carcinoma 1

RNA

:   Ribonucleic acid

Introduction {#s0001}
============

Expression of cancer testis antigen (CTA) genes in epithelial ovarian cancer (EOC) has been extensively characterized.[@cit0001] Patients harboring EOCs that express CTA genes demonstrate humoral and cell mediated immune responses, which can be associated with prolonged survival.[@cit0001] A number of vaccine studies targeting the CTA gene product NY-ESO-1 have been undertaken in EOC in order to enhance such anti-tumor immunity.[@cit0009] Variable outcomes in these trials may result from the observation that in CTA-expressing cancers, gene expression is heterogeneous, with some regions of the tumor expressing the antigen robustly, while others do not.[@cit0001] Furthermore, cancers may down-regulate NY-ESO-1 expression during the course of vaccine therapy.[@cit0013] Tumor-associated expression of CTA genes is often mediated by promoter hypomethylation, which is also influenced by the genome wide DNA methylation status.[@cit0014] Further supporting a role for DNA methylation in CTA gene regulation in EOC cells is the observation that the DNMTi decitabine (DAC, 5-aza-2′-deoxycitidine) induces CTA gene expression.[@cit0017] Importantly, DAC treatment not only leads to CTA gene expression, but also induced protein expression and functional presentation of CTA epitopes on the surface of cancer cells.[@cit0019] Enhancement of CTA-directed immunogenicity by DAC likely also involves the induction of class I Human Leukocyte Antigens (HLA) and co-stimulatory molecules by this agent.[@cit0020]

The above results have prompted considerable interest in the potential for clinical combination of CTA vaccine therapy with DNMTi.[@cit0022] DAC enhances expression of the CTA genes *NY-ESO-1* and *MAGE-A3/A6 in vitro* and in patients; however, the drug is given intravenously and it has a short half-life due to rapid inactivation by cytidine deaminase.[@cit0023] The other FDA-approved DNMTi, 5-azacytidine (AZA), can have similar effects on gene expression and DNA methylation; however the incorporation of this drug predominantly into RNA (∼85%) complicates its *in vivo* mechanism of action; like DAC, it has a short half-life.[@cit0023] Although DAC and AZA have shown significant activity in patients with myeloid cancers, Phase I single agent studies in solid tumors were disappointing, likely due to the relatively slower growth rate of solid tumors and the short half-life of both drugs.[@cit0024] To overcome these pharmacokinetic limitations, a rationally designed novel dinucleotide comprised of deoxy-guanosine complexed through a phosphodiester linker to DAC was synthesized.[@cit0027] This compound, SGI-110, allows longer half-life and more extended DAC exposure than DAC intravenous infusion, and the agent appears to be at least as active as DAC in inducing CTA genes *in vitro*.[@cit0021] Importantly, SGI-110 is administered subcutaneously and has activity in DAC-resistant leukemic patients.[@cit0028] The effect of SGI-110 on CTA\'s and its role as an immune modulator has been studied in melanoma and leukemia cell lines, but has not been investigated in ovarian cancer cells.[@cit0019] In the current study, we assessed the activity of SGI-110 for a variety of CTA related measures, using EOC cell lines grown *in vitro* or *in vivo* as xenografts. We find that SGI-110 causes CTA promoter and global DNA hypomethylation, CTA mRNA and protein expression, and cell surface expression of key immune-modulatory genes. Furthermore, drug treatment results in CTA-specific CD8+ T-cell cytotoxicity *in vitro*, and restricts tumor growth in combination with antigen-specific T-cells *in vivo*. The data thus indicate that SGI-110 is an attractive candidate for combination with CTA-directed vaccines in EOC.

Results {#s0002}
=======

SGI-110 treatment induces DNA hypomethylation and CTA mRNA and protein expression in EOC cell lines *in vitro* {#s0002-0001}
--------------------------------------------------------------------------------------------------------------

To evaluate the effect of SGI-110 treatment on CTA methylation, OVCAR3 and A2780 EOC cell lines were treated with 0.1, 1.0 and 5 μM SGI-110 for 6 days as described in Materials and Methods. Cell viability was also assessed after SGI-110 treatment on day 6 to compare with DAC and AZA treatment (**Fig. S1**). DAC and AZA doses were chosen as they were comparable with the plasma levels in patients.[@cit0029] *LINE-1* was used as a control for effects on global DNA methylation.[@cit0030] SGI-110 treatment resulted in a significant reduction of both *LINE-1* and *NY-ESO-1* promoter methylation, as assessed using quantitative bisulfite pyrosequencing ([**Fig. 1A**](#f0001){ref-type="fig"}). As pyrosequencing assays were not feasible for the *MAGE-A3/6* promoter (data not shown), we used MSP to analyze methylation of this locus. Similar to the other regions, *MAGE-A3/6* was hypomethylated following SGI-110 treatment in both EOC cell lines (**Fig. S2A**). As expected, AZA and DAC treatment also resulted in hypomethylation of these regions ([**Fig. 1A**](#f0001){ref-type="fig"}, **S2A**). To determine if hypomethylation of CTA genes by SGI-110 correlated with gene induction, we determined the mRNA and protein expression of NY-ESO-1 and MAGE-A. Both EOC cell lines demonstrated an increase in *NY-ESO-1* and *MAGE-A3/6* mRNA following SGI-110 treatment, and gene induction was greater than that observed with AZA or DAC ([**Fig. 1B**](#f0001){ref-type="fig"}). Both EOC cell lines also showed marked induction of NY-ESO-1 and MAGE-A protein ([**Fig. 1C**](#f0001){ref-type="fig"}). Notably, AZA was less potent at inducing CTA mRNA and protein expression, particularly in A2780 cells, although its effect on DNA methylation was similar. This could be due to the drug\'s off-target effects related to RNA incorporation. Figure 1.SGI-110 treatment induces DNA hypomethylation and expression of NY-ESO-1 and MAGE-A3/6 in EOC cell lines *in vitro*. OVCAR3 and A2780 cells were treated with SGI-110, DAC and AZA for 6 days as described in the Materials and Methods. (**A**) *LINE-1* and *NY-ESO-1* promoter methylation were determined by bisulfite pyrosequencing. (**B**) *NY-ESO-1* and *MAGE-A3/6* mRNA were quantified by RT-qPCR. (**C**) NY-ESO-1 and MAGE-A protein expression were determined by western blotting. All experiments were repeated at least 3 times. \**P* \< 0.05 vs. vehicle. S-SGI-110, V-Vehicle, DA-Decitabine, AZ-Azacitidine.

SGI-110 treatment induces DNA hypomethylation and CTA mRNA and protein expression in EOC xenografts using a daily x 5 days treatment schedule {#s0002-0002}
---------------------------------------------------------------------------------------------------------------------------------------------

We treated OVCAR3 xenograft-bearing SCID mice with a series of clinically relevant dosing schedules of SGI-110 or DAC (schedules tested in the Phase I/II trial for MDS or AML, see Materials and Methods).[@cit0031] We did not analyze AZA, as this drug was less potent *in vitro* in affecting CTA-related endpoints as compared to SGI-110 or DAC ([**Fig. 1**](#f0001){ref-type="fig"}). The effect of SGI-110 treatment on *LINE-1*, *NY-ESO-1*, and *MAGE-A3/6* methylation was evaluated in excised OVCAR3 tumors as mentioned above. Groups 1 to 5 (see [**Table 1**](#t0001){ref-type="table"} for Group description) were exposed subcutaneously to SGI-110 at doses of 3, 6.1, or 10 mg/kg, or DAC at 2.5 mg/kg, daily for 5 days and tumors were harvested on day 7. Due to differences in molecular weight, the molar equivalent of a 1mg dose of DAC is approximately 2.5 mg of SGI -110, thus the 6.1mg dose of SGI-110, approximates the 2.5 mg/kg DAC dose.[@cit0027] Mice treated on the 5 day schedule with SGI-110 at the 10 mg/kg/d dose developed significant gastrointestinal toxicity. Both DAC and SGI-110 treatment caused hypomethylation of *LINE-1* and *NY-ESO-1* at all doses ([**Fig. 2A**](#f0002){ref-type="fig"}*). MAGE-A3/6* hypomethylation was apparent at the 6.1 mg/kg SGI-110 dose (**Fig. S2B**). Tumors excised on day 7 demonstrated induction of *NY-ESO-1* and *MAGE-A3/A6* mRNA with SGI-110 treatment ([**Fig. 2B**](#f0002){ref-type="fig"}). Robust induction of CTA protein expression following SGI-110 treatment was also observed, and appeared to be more robust than that seen with DAC treatment ([**Fig. 2C**](#f0002){ref-type="fig"}). Table 1.Treatment schedule for xenograft experimentsGroupsTreatment mg/kg/dScheduleG1-5VehicleTreated daily for 5 days and tumor harvested on day 7.SGI-110-3SGI-110-6.1SGI-110-10DAC-2.5G6-10VehicleTreated once weekly for 3 weeks. One tumor was harvested on day 7 and the other on day 16.SGI-110-6.1SGI-110-12.2SGI-110-24.4DAC-5G11-15VehicleTreated twice weekly for 3 weeks. One tumor was harvested on day 7 and the other on day 16.SGI-110-6.1SGI-110-12.2SGI-110-24.4DAC-2.5 Figure 2.SGI-110 treatment induces hypomethylation and expression of *NY-ESO-1* and *MAGE-A3/6* in subcutaneous OVCAR3 xenografts treated using a daily x 5 schedule. SGI-110 at varying doses (3, 6.1,10 mg/kg) or DAC (2.5 mg/kg) was administered for 5 days, and tumors were harvested on day 7. (A) *LINE-1* and *NY-ESO-1* promoter methylation were determined by bisulfite pyrosequencing. (**B**) *NY-ESO-1* and *MAGE-A3/6* mRNA were quantified by RT-qPCR. C) NY-ESO-1 and MAGE-A protein expression were determined by western blotting. Data is representative of 3 animals/group. \**P* \< 0.05 vs. vehicle; \*\**P* \< 0.05 vs. DAC.

SGI-110 treatment induces DNA hypomethylation and CTA mRNA and protein expression in EOC xenografts using a weekly x 3 treatment schedule {#s0002-0003}
-----------------------------------------------------------------------------------------------------------------------------------------

Mice in treatment groups 6 to 10 received SGI-110 at 6.1, 12.2, or 24.4 mg/kg, or DAC at 5 mg/kg, once a week for 3 weeks. SGI-110 treatment resulted in significant *LINE-1* and *NY-ESO-1* hypomethylation on both days 7 and 16 post-treatment ([**Fig. 3A**](#f0003){ref-type="fig"}). SGI-110 at the highest dose (24.4 mg/kg) led to the greatest hypomethylation, without apparent toxicity (data not shown). Using MSP, we evaluated *MAGE-A3/6* promoter methylation and observed hypomethylation on both days 7 and 16 (**Fig. S2C**). This dosing schedule induced mRNA and protein expression of both CTA genes, particularly at the highest dose level ([**Fig. 3B--C**](#f0003){ref-type="fig"}). Figure 3.SGI-110 treatment induces hypomethylation and expression of *NY-ESO-1* and *MAGE-A3/6* in subcutaneous OVCAR3 xenografts treated using a weekly x 3 schedule. SGI-110 at varying doses (6.1, 12.2, 24.4 mg/kg) or DAC (5 mg/kg) was administered weekly for 3 weeks; tumors were harvested on days 7 and 16. (**A**) *LINE-1* and *NY-ESO-1* promoter methylation were determined by bisulfite pyrosequencing. (**B**) *NY-ESO-1* and *MAGE-A3/6* mRNA were determined by RT-qPCR. C) NY-ESO-1 and MAGE-A protein expression were determined by western blotting. Data represent 3 animals/group. \**P* \< 0.05 vs. vehicle; \*\**P* \< 0.05 vs. DAC.

SGI-110 treatment induces DNA hypomethylation and CTA mRNA and protein expression in EOC xenografts using a twice weekly x 3 treatment schedule {#s0002-0004}
-----------------------------------------------------------------------------------------------------------------------------------------------

Mice in groups 11 to 15 received SGI-110 at doses of 6.1, 12.2, 24.4 mg/kg, or DAC at 2.5 mg/kg, twice per week for 3 weeks, and tumors were harvested on days 7 and 16. Mice treated at the highest SGI-110 dose, 24.4mg/kg demonstrated significant morbidity by day 16 (data not shown). This schedule resulted in significant *LINE-1* and *NY-ESO-1* promoter hypomethylation at all SGI-110 doses ([**Fig. 4A**](#f0004){ref-type="fig"}). Additionally, SGI-110 at the 12.2 (molar equivalent of 4.9 mg DAC) and 24.4 mg/kg (molar equivalent to 9.8 mg/kg DAC) doses resulted in significantly greater hypomethylation than the DAC treatment control ([**Fig. 4A**](#f0004){ref-type="fig"}). *MAGE-A3/6* hypomethylation was also apparent using this schedule of SGI-110. (**Fig. S2D**). Again, hypomethylation of CTA promoters resulted in CTA gene induction at both the mRNA and protein levels ([**Fig. 4B--C**](#f0004){ref-type="fig"}). Specific SGI-110 treatment groups showed enhanced expression of CTA genes as compared to DAC. Unexpectedly, there was not a significant change in *MAGE-A3/6* mRNA expression at day 7 ([**Fig. 4B**](#f0004){ref-type="fig"}); however, MAGE-A protein expression was induced with all DNMTi treatments, and expression was sustained between days 7 and 16. This likely reflects the fact that the western blot assay detects many homologous MAGEA family members, while primers for *MAGE A3/6* are relatively specific.[@cit0032] Figure 4.SGI-110 treatment induces hypomethylation and expression of *NY-ESO-1* and *MAGE-A3/6* in subcutaneous OVCAR3 xenografts treated using a twice weekly x 3 week schedule. SGI-110 at varying doses (6.1, 12.2, 24.4 mg/kg) or DAC (2.5 mg/kg) was administered twice per week for 3 weeks, and tumors were harvested on days 7 and 16. (**A**) *LINE-1* and *NY-ESO-1* promoter methylation were determined by bisulfite pyrosequencing. (**B**) *NY-ESO-1* and *MAGE-A3/6* mRNA levels were determined by RT-qPCR. C) NY-ESO-1 and MAGE-A protein expression by western blotting. Data represent 3 animals/group. \**P* \< 0.05 vs. vehicle; \*\**P* \< 0.05 vs. DAC.

SGI-110 treatment enhances cell surface expression of MHC class I and ICAM-1 in EOC cells {#s0002-0005}
-----------------------------------------------------------------------------------------

To determine whether SGI-110 treatment enhanced the expression of MHC class I, HLA-A, B, C (HLA-ABC) and/or the costimulatory molecule ICAM-1 in EOC cells, we treated A2780 and OVCAR3 cells *in vitro* and measured pan HLA-ABC and ICAM-1 using flow cytometry. We observed SGI-110 concentration-dependent upregulation of HLA-ABC and ICAM-1 ([**Fig. 5A--B**](#f0005){ref-type="fig"}). In general, similar effects were observed following AZA and DAC treatment. Figure 5.SGI-110 enhances HLA-ABC and ICAM-1 expression, and NY-ESO-1-specific CD8+ T cell immune recognition, in EOC cells treated *in vitro*. OVCAR3 and A2780 cells were treated with SGI-110, DAC, or AZA, and expression of (**A**) HLA-ABC and (**B**) ICAM-1 were determined by flow cytometry. Data represent the Log2 transformation of \[median fluorescence intensity (MFI) of treatment / MFI of vehicle control\]. (**C**) OVCAR3 cells were treated with SGI-110, DAC, or AZA at the concentrations shown. Following treatment, cells were cultured with NY-ESO-1 specific, HLA compatible CD8+ T cell clones derived from ovarian cancer patients and relative CD107a/b expression was determined. All experiments were repeated 3 independent times. \**P* \< 0.05 vs. vehicle, NP-No peptide control.

SGI-110 treatment promotes NY-ESO-1-specific CD8+ T cell recognition of EOC cells {#s0002-0006}
---------------------------------------------------------------------------------

To determine if SGI-110 mediated induction of NY-ESO-1 and immune-modulatory molecules results in enhanced immune recognition, we co-cultured NY-ESO-1-specific CD8+ T-cells with OVCAR3 cells pretreated with DNMTi, and measured CD107a and CD107b expression, an established measure of antigen-specific CD8+ T cell-mediated cytolytic capacity.[@cit0033] SGI-110 treatment led to a significant increase in CD107a/b staining in NY-ESO-1 specific CD8+ T-cells as compared to vehicle control ([**Fig. 5C**](#f0005){ref-type="fig"}). A similar effect was observed with DAC treatment. These data indicate that SGI-110 treatment enhances NY-ESO-1 specific CD8+ T-cell recognition of HLA compatible tumor cells.

SGI-110 enhances NY-ESO-1-specific CD8+ T cell antitumor response *in vivo* {#s0002-0007}
---------------------------------------------------------------------------

Finally, we sought to determine if the observed increase in CTA expression and other immune molecules translated into enhanced tumor control *in vivo*. For this task, SCID mice with established OVCAR3 xenografts were treated with SGI-110 and/or NY-ESO-1-specific CD8+ T-cells. As 3.0 mg/kg SGI-110 daily x 5 induced *NY-ESO-1* expression *in vivo* without significant toxicity, we chose this dose for subcutaneous treatment of mice. Three days later, mice were injected intratumorally with NY-ESO-1-specific, HLA compatible, CD8+ T-cells or vehicle control (PBS). The combination of SGI-110 and NY-ESO-1 specific T-cells showed delayed tumor growth in comparison with mice treated with SGI-110 or NY-ESO-1-specific CD8 +T-cells alone ([**Fig. 6A**](#f0006){ref-type="fig"}). This delayed tumor growth was associated with a statistically significant increase in survival for mice treated with the combination of SGI-110 and NY-ESO-1-specific CD8+ T-cells ([**Fig. 6B**](#f0006){ref-type="fig"}). In these experiments, mice were sacrificed once the tumor diameter reached 2 cm and therefore longer survival reflects slower tumor growth. Together, these data suggest SGI-110 treatment enhances NY-ESO-1-specific antitumor responses *in vivo*. Figure 6.SGI-110 treatment enhances NY-ESO-1-specific antitumor response *in vivo*. SCID mice bearing established OVCAR3 tumors were treated with 3.0 mg/kg/d x 5 days SGI-110 or vehicle control (diluent) subcutaneously and, 3 days later, injected with NY-ESO-1-specific CD8+ T-cells or vehicle control (PBS) intra-tumorally. In total, there were 4 treatment groups: G1, vehicle; G2, NY-ESO-1-specific CD8+ T-cells; G3, SGI-110 and G4, SGI-110 and NY-ESO-1-specific CD8+ T-cells. (**A**) Absolute tumor volume over time in which drug treatment began on day 1 and NY-ESO-1-specific CD8+ T-cells were injected on day 8 and (**B**) Kaplan-Meier survival curves. p value as compared to G1.

Discussion {#s0003}
==========

We demonstrate herein that SGI-110 efficiently induces CTA promoter hypomethylation and gene expression in EOC cell lines *in vitro*. Furthermore we show that subcutaneous exposure of EOC tumor bearing mice to clinically relevant doses and schedules of SGI-110 leads to CTA promoter hypomethylation, mRNA, and protein expression. SGI-110 treatment also increases expression of HLA-ABC and ICAM-1, likely further promoting *in vitro* recognition of EOC cells by antigen specific CD8+ T-cell clones. Tumor-bearing SCID mice treated with SGI-110 and subsequently intra-tumorally injected with HLA-compatible NY-ESO-1 specific T-cell clones showed delayed tumor growth compared with SGI-110 treatment or CD8+ T-cells alone. Taken together, these data suggest that SGI-110 enhances immune recognition of cancer cells both by inducing the expression of tumor antigens and by upregulating MHC class I and immunomodulatory molecules. Interestingly, SGI-110 appeared to be more potent than DAC at inducing expression of the CTAs MAGE-A and NY-ESO-1, particularly at the protein level. All 3 of the tested *in vivo* administration schedules of SGI-110 (daily x 5; weekly x 3; twice weekly x 3) were efficient at causing CTA promoter hypomethylation and inducing CTA gene expression. All 3 schedules have been investigated in the recently completed Phase I/II clinical trial for AML and MDS, and the daily x 5 schedule has been taken forward; in contrast the weekly x 3 schedule produced minimal methylation changes and was discontinued.[@cit0032] In contrast, our current data support either of these schedules for potential combination with NY-ESO-1 vaccination in EOC patients. Prior reports supporting the notion that tumor specific T-cells and/or in combination with DAC can suppress tumor growth are consistent with our observations using SGI-110.[@cit0034] Additionally, Fang et al. recently reported that SGI-110 reduces ovarian tumors growth both alone and in combination with cisplatin, and can act as a chemosensitizer, demonstrating activity in other contexts for this agent in EOC.[@cit0036] Here we found that SGI-110 enhances NY-ESO-1 specific CD8+ T cell responses, and delayed tumor growth in a manor analogous to that reported in other contexts with DAC. Overall, these data have 2 major implications: i) induction of CTAs and related immune-modulatory activities should be considered as a potential mechanism of action of SGI-110 in ongoing trials of EOC and other solid tumors,[@cit0037] and ii) SGI-110 should be considered as a potential agent to augment the efficacy of CTA-directed vaccines in trials of EOC and other relevant tumor types, including melanoma and lung cancer.[@cit0021] The immunological effects of DNMTi are also supported by previous clinical studies of DAC.[@cit0039] In this context, we have recently shown in a Phase I trial that DAC combination therapy with NY-ESO-1 vaccine and liposomal doxorubicin is safe, promotes immunological responses, and may provide clinical benefit in EOC patients.[@cit0038] In addition to DNA methylation, CTA genes are regulated by other epigenetic mechanisms including histone acetylation, histone methylation, and nucleosome occupancy.[@cit0041] Thus, agents that impinge on these processes may also be useful for combination with CTA-directed vaccination strategies. In summary, the current data suggest that SGI-110 is a promising agent to incorporate into the spectrum of novel epigenetic/immunological approaches for EOC.

Materials and Methods {#s0004}
=====================

Cell lines and *in vitro* drug treatments {#s0004-0001}
-----------------------------------------

OVCAR3 and A2780 EOC cell lines were propagated in DMEM supplemented with 10% Fetal Bovine Serum (FBS), 2 mM [L]{.smallcaps}, and 1% Penicillin-Streptomycin. SGI-110 was provided by Astex Pharmaceuticals, Inc.. (Dublin, CA). AZA and DAC were obtained from Sigma. Cell lines were treated with SGI-110 at concentration 0.1, 1.0 and 5 μmol/L (in PBS) on day 2 and day 4, and harvested on day 6. As controls, cells were treated with vehicle alone, 0.5 μmol/L DAC, and 2.0 μmol/L AZA using the same treatment schedule as SGI-110. Trypan blue exclusion was used to evaluate cell viability (**Fig. S1**).

Xenograft experiments {#s0004-0002}
---------------------

A total of 1 × 10^6^ OVCAR3 cells suspended in Matrigel (BD Biosciences) were implanted into the hindquarters of 6 week old female SCID mice using an IACUC-approved protocol. After ∼2--3 weeks, when macroscopic tumors were formed (∼50 mm^3^), mice were assigned into the different groups ([**Table 1**](#t0001){ref-type="table"}). All treatment groups were exposed to vehicle, SGI-110 or DAC subcutaneously. For groups 1--5 a single tumor was implanted in one hindquarter and for groups 6--15 2 tumors were implanted, one in each hindquarter. Tumors were excised for molecular analysis on day 7 for Groups 1--5, and on days 7 and 16 for Groups 6--15.

DNA Methylation Analysis {#s0004-0003}
------------------------

Genomic DNA was isolated using the Puregene kit (Qiagen) and sodium bisulfite conversion was performed using the EZ DNA Methylation Kit (Zymo Research). *NY-ESO-1* promoter and *LINE-1* repetitive element DNA methylation were determined by sodium bisulfite pyrosequencing as described previously.[@cit0002] To evaluate *MAGE-A3/6* promoter methylation, MSP was performed as previously described.[@cit0044] Primers were designed using *MethPrimer*.[@cit0045] Primer sequences were used as previously reported.[@cit0019] Unmethylated and methylated PCR products were amplified with initial denaturation at 95˚C for 5 min, then 35 cycles of denaturation at 95˚C for 30 s, annealing at 60˚C for 30 s and extension at 72˚C for 60 s, followed by a final 5 min extension at 72˚C. PCR products were analyzed on 2% agarose gel by ethidium bromide staining.

Reverse Transcriptase quantitative PCR (RT-qPCR) {#s0004-0004}
------------------------------------------------

Total RNA was purified using Trizol (Invitrogen) and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad). Absolute quantification was performed using PCR Master Mix for SYBR Green assays (Eurogentech) on 7300 Real-Time PCR System (Applied Biosciences). All samples were run in triplicate, and *NY-ESO-1* and *MAGE-A-3/6* gene expression data were normalized to *18SrRNA.* Primer sequences used were reported previously.[@cit0019]

Western blot analysis {#s0004-0005}
---------------------

Total cellular protein was extracted from cell lines and/ or tissue samples using NP-40 lysis buffer and quantitated, and protein expression for NY-ESO-1 and MAGE-A was evaluated as described previously.[@cit0019] **Figure S3** shows representative blots with molecular weight of the proteins studied along with molecular weight marker.

Flow cytometry {#s0004-0006}
--------------

Cells were harvested and stained with anti-human HLA-ABC (clone W6/32) or anti-human CD54 (alternatively known as ICAM-1, clone HA58) antibodies (eBioscience) and changes in the expression of HLA-ABC and ICAM-1 following DNMTi treatment was determined as described previously.[@cit0019] Representative gating is shown in **Figure S4**.

NY-ESO-1-specific CD8+ T cell recognition assay {#s0004-0007}
-----------------------------------------------

NY-ESO-1-specific HLA-A2-restricted CD8+ T-cells were prepared as described previously[@cit0011], and HLA-A2 positive OVCAR3 cells were treated with AZA, DAC, or varying doses of SGI-110 as described above. Following treatment, cells were co-cultured for 6 hours at 37°C in the presence of anti-CD107a and CD107b antibodies (BD Biosciences), monensin, and brefeldin A (Sigma). Negative control stimulations with no peptide and positive control stimulations with peptide (NY-ESO-1~157-165~) or phorbol myristate acetate and ionomycin were analyzed in parallel. Using NY-ESO-1-specific CD8+ T-cells (identified as tetramer+ CD8+ cells), CD107a/b+ was determined and normalized to positive control which served as an internal control from each independent experiment.

NY-ESO-1-specific CD8 +T cell antitumor response {#s0004-0008}
------------------------------------------------

OVCAR3 cells (1 × 10^6^) suspended in PBS were subcutaneously implanted into the flanks of 5 week old female SCID mice using an IACUC-approved protocol. After ∼2--3 weeks, when macroscopic tumors formed, mice were treated daily with either 3.0 mg/kg/d SGI-110 or vehicle control (diluent) and, 3 days later, intra-tumorally injected with 2 × 10^6^ NY-ESO-1-specific CD8 +T-cells or vehicle control (PBS). In total, there were 4 treatment groups (which included at least 7 mice/group): G1, vehicle (diluent and PBS); G2, NY-ESO-1-specific CD8+ T-cells (diluent and NY-ESO-1-specific CD8+ T-cells); G3, SGI-110 (SGI-110 and PBS) and G4, SGI-110 and NY-ESO-1-specific CD8 +T-cells. Tumors were measured according to the shortest (A) and longest diameter (B) to determine tumor volume (V) in which V = (A^2^B)/2. Survival was determined on the basis of tumor diameter. If a tumor reached 2cm in diameter, the mouse was euthanized.

Statistical analysis {#s0004-0009}
--------------------

Statistical analysis was performed by analysis of variance using GraphPad Prism. Differences between the 2 groups were analyzed using the t test. All data are presented as mean ± standard error. Difference between HLA-ABC and ICAM1 expression fold change was analyzed using one sample t test. The statistical significance of Kaplan-Meier survival curves was determined using log-rank (Mantel-Cox) test.
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